Gastroesophageal reflux disease management according to contemporary international guidelines: A translational study

Table 1 Proton pump inhibitor types and equivalent doses used for maintenance therapy n (%)

PPI types and doses	Acute phase	Maintenance phase
Esomeprazole 40 mg	149 (26.94)	10 (2.16)
Esomeprazole 20 mg	20 (3.62)	141 (30.45)
Omeprazole 20 mg	314 (56.78)	33 (7.13)
Omeprazole 10 mg	1 (0.18)	211 (45.57)
Lansoprazole 30 mg	13 (2.35)	4 (0.86)
Lansoprazole 15 mg	1 (0.18)	14 (3.02)
Pantoprazole 40 mg	39 (7.05)	1 (0.22)
Pantoprazole 20 mg	1 (0.18)	35 (7.56)
Rabeprazole 20 mg	15 (2.71)	1 (0.22)
Rabeprazole 10 mg		13 (2.81)

Table 2 Study population demographics and features according to endoscopic results n (%)

	EE	NERD	P
	(306/577, 53%)	(271/577, 47%)
Male	194 (63.4)	101 (37.3)	< 0.05
Female	112 (36.6)	170 (62.7)	< 0.05
Age (yr), mean (± SD)	43.6 (± 2.22)	43.42 (± 12.56)	NS
Height (cm), mean (± SD)	169.86 (± 8.63)	166.84 (± 8.14)	NS
Weight (kg), mean (± SD)	75.33 (± 15.40)	68.49 (± 12.41)	NS
Smoking	164 (48.1)	115 (39.2)	NS
Esophagitis severity (Savary-Miller classification)
Grade 1	237 (77.5)	-	NS
Grade 2	52 (16.9)	-	NS
Grade 3	9 (2.9)	-	NS
Grade 4	8 (2.6)	-	NS
H. pylori presence	51 (14.9)	37 (12.6 )	NS
Heartburn intensity
1 = mild	28 (9.2)	33 (12.1)	NS
2 = moderate	181 (59.1)	166 (61.2 )	NS
3 = severe	88 (28.7)	64 (23.6)	NS
4 = unbearable	9 (2.9)	8 (2.9)	NS
Regurgitation	248 (81)	227 (83.7)	NS
Chest pain	146 (47.7)	120 (44.3)	NS
Dysphagia	99 (32.3)	95 (35)	NS
Belching	198 (64.7)	181 (66.7)	NS
Chronic cough	102 (33)	85 (31.4)	NS
Hoarseness	89 (29)	102 (37.6)	NS

EE: Erosive esophagitis; NERD: Non erosive reflux disease; NS: Not significant.

Table 3 Dropout causes

Dropout cause	n (%)
Personal reasons	12 (6.7)
Therapy failure	1 (0.6)
Patient fails to follow-up visit	46 (25.7)
Prolonged time to visit	60 (33.5)
Adverse reaction	2 (1.1)
Other	58 (32.4)
Total	179 (100)